Femasys Gains FDA Clearance for Integrated Fallopian Tube Diagnostic
Event summary
- Femasys received 510(k) clearance from the FDA for the FemVue Controlled diagnostic device on December 18, 2025.
- The device integrates the company’s existing FemVue and FemChec technologies into a single platform.
- FemVue Controlled is designed to evaluate fallopian tube status using controlled contrast delivery during ultrasound imaging.
- The device is intended to streamline workflows and enable multiple clinical uses, including confirmation of tubal patency prior to FemaSeed use.
The big picture
Femasys's focus on non-surgical contraception and fertility treatments addresses a growing market demand for less invasive and more accessible options. The integration of FemVue and FemChec into a single device represents a strategic move to improve operational efficiency and expand the utility of its diagnostic portfolio. This clearance strengthens Femasys’s position in a competitive landscape, but the company’s long-term success hinges on successful commercialization and regulatory approvals for its broader product pipeline, including FemBloc.
What we're watching
- Commercialization
- The speed of adoption by clinicians will be key to realizing the device's potential to streamline workflows and increase Femasys’s market penetration within the fertility and contraception space.
- Regulatory Risk
- The ongoing FINALE trial for FemBloc’s U.S. FDA approval presents a significant regulatory hurdle, and any setbacks could impact investor sentiment surrounding the broader Femasys portfolio.
- Integration
- How effectively Femasys integrates the FemVue Controlled device into its existing product offerings, particularly alongside FemaSeed, will determine its overall impact on revenue and market share.
Related topics